Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat people with relapsed or refractory multiple myeloma, according to data from two clinical trials. Findings from both trials — DREAMM-2 (NCT03525678) and DREAMM-6 (NCT03544281) — were presented in two posters at the recent 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held online. An antibody-drug conjugate, belantamab mafodotin is made up…
You must be logged in to read/download the full post.
The post Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials appeared first on BioNewsFeeds.